XIAP and cancer: One such treatment is the drug xevinapant, a first-in-class non-specific inhibitor of three inhibitors of apoptosis proteins (cIAP1, cIAP2, and XIAP), which sensitizes cancer cells to the cytotoxic effects of chemotherapy and radiotherapy-induced DNA damage.